Full Press Release Details
DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million
Initiates Q4'25 Adjusted Revenue(3) Guidance of 31% to 43% Q-o-Q Growth
13 Million HYPE Tokens Staked to Hyperion's Validator as of October 31, 2025
Business Lines Expected to Achieve Positive Operating Cash Flows in 2026
HILLS, Calif., November 13, 2025 -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"),
the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today reported
results for the third quarter ending September 30, 2025.
has been an extraordinary six months for Hyperion DeFi, and we are still in the early stages of our evolution," said Hyunsu Jung, Interim
CEO of Hyperion DeFi.
continued, "We've successfully executed what we believe represents one of the most significant corporate transformations in recent
public market history - pivoting from Eyenovia's ophthalmic technology focus to establishing ourselves as a premier institutional gateway
to DeFi innovation. In our first full quarter with our new digital asset treasury strategy, not only did we achieve record net income
for the Company, but we have established multiple business lines on the Hyperliquid blockchain which we expect to continue to scale through
the fourth quarter, into 2026, and beyond."
Operating & Financial Results(1)
| Q3 2025 | ||||
| (Unless Otherwise Indicated) | ||||
| HYPE - Digital Assets (2) | $ | 37,954,590 | ||
| Gross HYPE Holdings (3) | $ | 77,751,604 | ||
| Gross HYPE Tokens (5) | 1,720,549 | |||
| HYPE Tokens Staked at Kinetiq x Hyperion Validator as of 9/30 (4) | 8,249,233 | |||
| HYPE Tokens Staked at Kinetiq x Hyperion Validator as of 10/31 (4) | 13,210,917 | |||
| Net Asset Value (3) | $ | 74,545,583 | ||
| Revenue | $ | 302,506 | ||
| Adjusted Revenue (3) | $ | 361,277 | ||
| Income From Operations | $ | 4,428,191 | ||
| Net Income | $ | 6,625,582 | ||
| Net Income Attributable to Participating Securities | $ | 5,830,582 | ||
| Weighted Average Common Shares Outstanding - Basic | 6,027,713 | |||
| Weighted Average Common Shares Outstanding - Diluted | 28,951,915 | |||
| Net Income Per Common Share - Basic | $ | 0.26 | ||
| Net Income Per Common Share - Diluted | $ | 0.05 | ||
| Adjusted EBITDA (3) | $ | 7,951,003 |
financial information in this press release is unaudited. Throughout this document, totals may not sum due to rounding. Calculations
are based on unrounded results. N.M. is the abbreviation for "Not Meaningful".
- Digital Assets", a GAAP measure, does not include HiHYPE, which is Hyperion's liquid staking HYPE token.
"Non-GAAP Financial Measures" below for an explanation and reconciliations of non-GAAP measures used throughout this press
operating disclosure; information on the number of tokens staked at the Company's validator is available real-time via public sources.
supplemental disclosure more fully described on the Reconciliation of GAAP HYPE - Digital Assets to Non-GAAP Gross HYPE Holdings.
of Business Activities in Q3'25
DeFi is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. The
Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest
revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native
staking yield and additional revenues generated from its unique on-chain utility.
Company's Q3'25 operating business activities are summarized below:
DeFi, Inc. will host a conference call to discuss third quarter 2025 results at 5:00 p.m. Eastern Time on November 13,
2025. A slide presentation that includes supplemental financial information and reconciliations of certain non-GAAP measures to their
most directly comparable GAAP measures can be accessed through the Company's Investor Relations website at https://ir.hyperiondefi.com/events-and-presentations
along with information for the conference call. Participants may submit questions in advance of the call via email to IR@hyperiondefi.com.
A webcast of the call will be archived and available through Thursday, November 27, 2025 at 11:59 on the Company's website.
growth rates represent year-over-year comparisons, except as otherwise noted. All amounts in tables are presented in U.S. dollars, rounded
to the nearest dollar, except as otherwise noted. As a result, certain amounts and rates may not sum or recalculate using the rounded
dollar amounts provided.
the Hyperliquid Platform and the HYPE Token
is a next-generation layer one blockchain optimized for high frequency, transparent trading. The blockchain includes fully on-chain perpetual
futures and spot order books, with every order, cancel, trade, and liquidation occurring within 70 millisecond block times. It also hosts
the HyperEVM, a general-purpose smart contract platform that supports permissionless decentralized financial applications akin to Ethereum.
is the native token of Hyperliquid. Staked HYPE provides utility for users via reduced trading fees and increased referral bonuses. As
of October 2025, more than 30 million HYPE have been autonomously purchased and sequestered by the blockchain with the trading fees
generated on the network's central limit order books.
DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of HYPE. The Company provides investors
with streamlined access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world.
Shareholders benefit from compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its
unique on-chain utility.
DeFi is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic
liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases
due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together,
these benefits may result in higher treatment compliance and better outcomes for patients and providers.
more information, please visit Hyperiondefi.com.
Looking Statements; Disclaimer
for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements.
Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies,
predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities
for our platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, and the growth and revenue
potential of the Hyperliquid ecosystem and the growth prospects of the Company. These statements are based on current expectations, estimates
and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance
and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some
cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors
discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission (the "SEC").
forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities
laws, Hyperion DeFi does not undertake any obligation to update any forward-looking statements.
information contained in this press release and statements made orally during the corresponding earnings call relate to or are based
on studies, publications, surveys and other data obtained from third-party sources and Hyperion DeFi's own internal estimates and
research. While Hyperion DeFi believes these third-party studies, publications, surveys and other data to be reliable as of the date
of this press release, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness
of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy
of Hyperion DeFi's internal estimates or research and no reliance should be made on any information or statements made in this
press release relating to or based on such internal estimates and research. You should conduct your own investigation and analysis of
Hyperion DeFi, its business, prospects, results of operations and financial condition. In furnishing this information, Hyperion DeFi
does not undertake any obligation to provide you with access to any additional information (including forward-looking information and
any projections contained herein) or to update or correct the information.
DeFi, Inc. Investor Contact:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 8,223,180 | $ | 2,121,463 | ||||
| Prepaid expenses and other current assets | 862,587 | 645,736 | ||||||
| Total Current Assets | 9,085,767 | 2,767,199 | ||||||
| HYPE - digital assets | 37,954,590 | - | ||||||
| Digital intangible assets | 35,019,932 | - | ||||||
| Operating lease right-of-use asset | 491,589 | 718,360 | ||||||
| Other assets | 238,029 | 182,200 | ||||||
| Total Assets | $ | 82,789,907 | $ | 3,667,759 | ||||
| Liabilities and Stockholders' Equity (Deficit) | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 1,138,750 | $ | 1,954,681 | ||||
| Accrued former licensor obligations | - | 2,245,087 | ||||||
| Accrued expenses and other current liabilities | 2,403,686 | 1,322,674 | ||||||
| Operating lease liabilities - current portion | 494,656 | 575,163 | ||||||
| Notes payable - current portion, net of debt discount of $0 and $527,870 as of September 30, 2025 and December 31, 2024, respectively | - | 5,212,532 | ||||||
| Convertible notes payable - current portion, net of debt discount of $0 and $263,930 as of September 30, 2025 and December 31, 2024, respectively | - | 4,736,070 | ||||||
| Total Current Liabilities | 4,037,092 | 16,046,207 | ||||||
| Notes payable - non-current portion, net of debt discount of $598,691 and $0 as of September 30, 2025 and December 31, 2024, respectively | 7,656,005 | - | ||||||
| Operating lease liabilities - non-current portion | 341,778 | 717,504 | ||||||
| Total Liabilities | 12,034,875 | 16,763,711 | ||||||
| Commitments and contingencies (Note 9) | ||||||||
| Stockholders' Equity (Deficit): | ||||||||
| Preferred stock, $0.0001 par value, 60,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock, 5,435,898 shares designated, and 5,435,897 and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 544 | - | ||||||
| Common stock, $0.0001 par value, 600,000,000 shares authorized; 7,162,659 and 1,506,369 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 715 | 151 | ||||||
| Additional paid-in capital | 271,612,635 | 182,213,889 | ||||||
| Accumulated deficit | (200,858,862 | ) | (195,309,992 | ) | ||||
| Total Stockholders' Equity (Deficit) | 70,755,032 | (13,095,952 | ) | |||||
| Total Liabilities and Stockholders' Equity (Deficit) | $ | 82,789,907 | $ | 3,667,759 |
Statement of Operations
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 302,506 | 1,625 | $ | 317,226 | $ | 29,243 | |||||||||
| Cost of revenue | - | (132,522 | ) | (48 | ) | (825,910 | ) | |||||||||
| Gross Profit (Loss) | 302,506 | (130,897 | ) | 317,178 | (796,667 | ) | ||||||||||
| Operating (Income) Expenses: | ||||||||||||||||
| Research and development | 373,855 | 3,471,939 | 1,721,476 | 12,500,713 | ||||||||||||
| Selling, general and administrative | 2,594,130 | 3,729,091 | 12,645,156 | 11,125,115 | ||||||||||||
| Realized gains - digital assets | (6,942,713 | ) | - | (6,942,713 | ) | - | ||||||||||
| Unrealized gains - digital assets | (6,440,804 | ) | - | (6,440,804 | ) | - | ||||||||||
| Impairment loss - digital intangible assets | 6,289,847 | - | 6,289,847 | - | ||||||||||||
| Reacquisition of license rights | - | - | - | 4,864,600 | ||||||||||||
| Net Operating (Income) Expenses | (4,125,685 | ) | 7,201,030 | 7,272,962 | 28,490,428 | |||||||||||
| Income (Loss) From Operations | 4,428,191 | (7,331,927 | ) | (6,955,784 | ) | (29,287,095 | ) | |||||||||
| Other Income (Expense): | ||||||||||||||||
| Other income (expense), net | 131,525 | 1,184 | 304,052 | (93,394 | ) | |||||||||||
| Gain on extinguishment of liability | 2,245,088 | - | 2,334,711 | - | ||||||||||||
| Change in fair value of equity consideration payable | - | - | - | 1,240,800 | ||||||||||||
| Interest expense | (223,080 | ) | (602,109 | ) | (1,332,989 | ) | (1,954,768 | ) | ||||||||
| Interest income | 43,858 | 44,999 | 101,140 | 230,804 | ||||||||||||
| Total Other Income (Expense), Net | 2,197,391 | (555,926 | ) | 1,406,914 | (576,558 | ) | ||||||||||
| Net Income (Loss) | 6,625,582 | (7,887,853 | ) | (5,548,870 | ) | (29,863,653 | ) | |||||||||
| Dividend to preferred stockholders | (795,000 | ) | - | (892,167 | ) | - | ||||||||||
| Net Income (Loss) Attributable to Participating Securities | $ | 5,830,582 | $ | (7,887,853 | ) | $ | (6,441,037 | ) | $ | (29,863,653 | ) | |||||
| Net Income (Loss) per Common Share | ||||||||||||||||
| Basic | $ | 0.26 | $ | (9.07 | ) | $ | (1.64 | ) | $ | (42.30 | ) | |||||
| Diluted | $ | 0.05 | $ | (9.07 | ) | $ | (1.64 | ) | $ | (42.30 | ) | |||||
| Weighted Average Number of Common Shares Outstanding: | ||||||||||||||||
| Basic | 6,027,713 | 869,479 | 3,930,764 | 705,961 | ||||||||||||
| Diluted | 28,951,915 | 869,479 | 3,930,764 | 705,961 |
Statements of Changes in Stockholders' Equity (Deficiency)
the Three and Nine Months Ended September 30, 2025
| Additional | Total | |||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Paid-In | Accumulated | Stockholders' | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity (Deficit) | ||||||||||||||||||||||
| Balance - January 1, 2025 | - | $ | - | 1,506,369 | $ | 151 | $ | 182,213,889 | $ | (195,309,992 | ) | $ | (13,095,952 | ) | ||||||||||||||
| Issuance of common stock in At the Market offering [1] | - | - | 1,127,100 | 113 | 5,663,153 | - | 5,663,266 | |||||||||||||||||||||
| Induced exercise of stock warrants [2] | - | - | 197,118 | 19 | 922,731 | - | 922,750 | |||||||||||||||||||||
| Reverse stock split settlement of fractional shares | - | - | (41 | ) | - | (160 | ) | - | (160 | ) | ||||||||||||||||||
| Stock-based compensation | - | - | - | - | 279,628 | - | 279,628 | |||||||||||||||||||||
| Net loss | - | - | - | - | - | (3,483,533 | ) | (3,483,533 | ) | |||||||||||||||||||
| Balance - March 31, 2025 | - | - | 2,830,546 | 283 | 189,079,241 | (198,793,525 | ) | (9,714,001 | ) | |||||||||||||||||||
| Issuance of preferred stock and warrants in private placement [3] | 5,435,897 | 544 | - | - | 49,365,206 | - | 49,365,750 | |||||||||||||||||||||
| Issuance of common stock in At the Market offering [4] | - | - | 1,323,389 | 132 | 2,559,008 | - | 2,559,140 | |||||||||||||||||||||
| Issuance of common stock from exercise of warrants | - | - | 252,000 | 25 | 1,953,479 | - | 1,953,504 | |||||||||||||||||||||
| Issuance of common stock from the delivery of vested restricted stock units | - | - | 44,072 | 4 | (4 | ) | - | - | ||||||||||||||||||||
| Issuance of common stock from the partial conversion of note payable | - | - | 404,820 | 41 | 640,295 | - | 640,336 | |||||||||||||||||||||
| Warrants issued in consideration for debt modification | - | - | - | - | 858,270 | - | 858,270 | |||||||||||||||||||||
| Stock-based compensation | - | - | - | - | 483,654 | - | 483,654 | |||||||||||||||||||||
| Net loss | - | - | - | - | - | (8,690,919 | ) | (8,690,919 | ) | |||||||||||||||||||
| Preferred stock dividend | - | - | - | - | (97,167 | ) | - | (97,167 | ) | |||||||||||||||||||
| Balance - June 30, 2025 | 5,435,897 | 544 | 4,854,827 | 485 | 244,841,982 | (207,484,444 | ) | 37,358,567 | ||||||||||||||||||||
| Issuance of common stock in At the Market offering [5] | - | - | 1,929,207 | 192 | 21,783,753 | - | 21,783,945 | |||||||||||||||||||||
| Issuance of common stock from exercise of warrants [6] | - | - | 250,125 | 25 | 1,938,944 | - | 1,938,969 | |||||||||||||||||||||
| Issuance of common stock from the delivery of vested restricted stock units | - | - | 128,500 | 13 | (13 | ) | - | - | ||||||||||||||||||||
| Stock-based compensation | - | - | - | - | 3,842,969 | - | 3,842,969 | |||||||||||||||||||||
| Net income | - | - | - | - | - | 6,625,582 | 6,625,582 | |||||||||||||||||||||
| Preferred stock dividend | - | - | - | - | (795,000 | ) | - | (795,000 | ) | |||||||||||||||||||
| Balance - September 30, 2025 | 5,435,897 | $ | 544 | 7,162,659 | $ | 715 | $ | 271,612,635 | $ | (200,858,862 | ) | $ | 70,755,032 |
Includes gross proceeds of $5,851,007 less total issuance costs of $187,741.
Includes gross proceeds of $1,039,206 less total issuance costs of $116,456. Also note that incremental value and non-cash warrant modification
and additional warrants issuance costs related to the warrant inducement entered into on January 16, 2025 offset to a zero balance.
Includes gross proceeds of $50,000,000 less total issuance costs of $634,250.
Includes gross proceeds of $2,657,659 less total issuance costs of $98,519.
Includes gross proceeds of $22,489,548 less total issuance costs of $705,603.
Partial exercise of the Armistice warrants.
Statements of Changes in Stockholders' Equity (Deficiency)
the Three and Nine Months Ended September 30, 2024
| Additional | Total | |||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Paid-In | Accumulated | Stockholders' | ||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity (Deficit) | ||||||||||||||||||||||
| Balance - January 1, 2024 | - | $ | - | 569,409 | $ | 57 | $ | 154,490,596 | $ | (145,491,559 | ) | $ | 8,999,094 | |||||||||||||||
| Issuance of common stock in At the Market offering [7] | - | - | 22,917 | 2 | 3,194,545 | - | 3,194,547 | |||||||||||||||||||||
| Cashless exercise of stock options | - | - | - | - | - | |||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | 546,232 | - | 546,232 | |||||||||||||||||||||
| Issuance of common stock related to vested restricted stock units | - | - | - | - | - | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | (10,922,101 | ) | (10,922,101 | ) | |||||||||||||||||||
| Balance - March 31, 2024 | - | - | 592,326 | 59 | 158,231,373 | (156,413,660 | ) | 1,817,772 | ||||||||||||||||||||
| Issuance of common stock in registered direct offering [8] | - | - | 40,297 | 4 | 1,888,825 | - | 1,888,829 | |||||||||||||||||||||
| Issuance of common stock as consideration for licensing agreement [9] | - | - | 7,669 | 1 | 436,808 | - | 436,809 | |||||||||||||||||||||
| Issuance of common stock as consideration for reacquisition of licensing agreement [10] | - | - | 28,742 | 3 | 2,322,388 | - | 2,322,391 | |||||||||||||||||||||
| Issuance of common stock in At the Market offering [11] | - | - | 28,687 | 3 | 1,676,936 | - | 1,676,939 | |||||||||||||||||||||
| Stock-based compensation | - | - | - | - | 541,056 | - | 541,056 | |||||||||||||||||||||
| Net loss | - | - | - | - | - | (11,053,699 | ) | (11,053,699 | ) | |||||||||||||||||||
| Balance - June 30, 2024 | - | - | 697,720 | 70 | 165,097,386 | (167,467,359 | ) | (2,369,903 | ) | |||||||||||||||||||
| Issuance of common stock and warrants in offerings [12] | - | - | 363,197 | 36 | 12,348,142 | - | 12,348,178 | |||||||||||||||||||||
| Warrant modification - incremental value [13] | - | - | - | - | 2,868,000 | - | 2,868,000 | |||||||||||||||||||||
| Warrant modification - in issuance costs for registered direct offering [14] | - | - | - | - | (2,868,000 | ) | - | (2,868,000 | ) | |||||||||||||||||||
| Issuance of common stock in At the Market offering [15] | - | - | 18,779 | 2 | 1,175,881 | - | 1,175,883 | |||||||||||||||||||||
| Stock-based compensation | - | - | - | - | 452,998 | - | 452,998 | |||||||||||||||||||||
| Net loss | - | - | - | - | - | (7,887,853 | ) | (7,887,853 | ) | |||||||||||||||||||
| Balance - September 30, 2024 | - | $ | - | 1,079,696 | $ | 108 | $ | 179,074,407 | $ | (175,355,212 | ) | $ | 3,719,303 |
Includes gross proceeds of $3,293,347 less total issuance costs of $98,800.
Includes gross proceeds of $2,000,000 less total issuance costs of $111,171.
Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.
Shares issued in partial consideration for reacquisition of License Agreement with Bausch & Lomb Ireland Limited.
Includes gross proceeds of $1,728,804 less total issuance costs of $51,868.
Includes gross proceeds of $14,139,994 less total issuance costs of $1,791,816.
Offering includes modification of warrants and additional warrants in the July 2024 offering.
Non-cash warrant modification and additional warrants issuance costs related to one of the offerings of $2,868,000 are shown on a separate
Includes gross proceeds of $1,212,251 less total issuance costs of $36,368.